Transforming
the Breast Cancer Paradigm
Our mission is to develop innovative medicines in areas of significant unmet medical needs in oncology.
- Advanced programs
- Prevention and Treatment
- Innovative Approach
- Experienced Leadership
The Breast Cancer Problem
78%
of US breast cancer is ER+
1 in 8
women experience breast cancer
281,000
women diagnosed in US annually
2nd
leading cause of cancer death in American women
Our Lead Program
Atossa’s primary focus is the development of our proprietary (Z)-endoxifen in multiple breast cancer settings.
Breast Cancer
We are developing the promise of (Z)-endoxifen in two different settings and exploiting its potential to both help prevent as well as treat breast cancer with our proprietary Oral (Z)-endoxifen.
The two settings of (Z)-endoxifen include Neoadjuvant ER+/HER2- and Mammographic Breast Density(MBD).